Newsletter | February 27, 2020

02.27.20 -- How Kaiser Permanente Built A Biosimilar Empire

 
Featured Editorial
How Kaiser Built A Biosimilar Empire: The Inside Story
 
By Anna Rose Welch, editor, Biosimilar Development
Kaiser Permanente's Dr. Sameer Awsare and I touched base in recent weeks to talk about the process in place that has encouraged great success for biosimilars within KP.
Biosimilar Litigation Review: Anticompetitive Conduct Cases And Post-Grant Patent Challenges
 
By P. Chen, F. Eyzaguirre, T. Francis, and J. Shmuel, Fish & Richardson
This is the fourth article in a four-part series on 2019 legal developments related to the biosimilar sector. In this final installment we cover 2019 biosimilar litigation related to anticompetitive conduct and post-grant patent challenges at the Patent Trial and Appeal Board (PTAB), and we look ahead to what biosimilar developers can anticipate in 2020.
Biosimilars Made Simple: A Microanalysis Of Biosimilars And Relevant Policy
 
By Lanton Law

With all the promise biosimilars hold, why are we not seeing increased market uptake? There are many reasons that involve policy, legislation, and the legal system that have led to the current state of the biosimilar market in the U.S. This white paper examines the basics.

Industry Insights
Addressing New Chromatography Challenges With Fiber Absorbents
White Paper | By Iwan Roberts, GE Healthcare Life Sciences

An absorbent material using a novel proprietary structure overcomes the diffusional and flow limitations of packed bed chromatography purification systems and aims to address the capacity issues.

Don’t Let Insufficient Data Undermine Your CMO And CRO Selection Processes
Article | By Kevin Olson, ISR Reports

Selecting a partner is challenging, but with the right information you can simplify your efforts and increase your likelihood of making the best decision. 

Is Your Biologic At Risk For Protein Aggregation? Part 2
Article | By Martin Gonzalez, Ph.D., Pfizer CentreOne Contract Manufacturing

How to prevent protein aggregation via considerations for the manufacturing process and container selection criteria. Part two of a three-part series.

Connect With Biosimilar Development:
      Twitter